Tenofovir to Prevent HBV Reactivation
Study Description
“Tenofovir to Prevent HBV Reactivation”
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma or CLL/SLL. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.
Location
Methods
Pharmaceutical medication involved
Recruiting patients only
Drug - Tenofovir disoproxil
Drug - Placebo Oral Tablet
Additional Information
Official Study Title
A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Clinical Trial ID
NCT02186574
ParticipAid ID
wdLPWd
